Navigation Links
RBC Life Sciences Announces 2009 Year End Results

IRVING, Texas, March 11 /PRNewswire-FirstCall/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) — RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $24.9 million for the year ended December 31, 2009, compared to net sales of $30.4 million for the same period during 2008.

The company also reported a net loss of $335,000, or $0.02 per diluted share, during 2009, compared to net earnings of $1.6 million, or $0.07 per diluted share, during 2008.

"In 2009, our international licensees were hobbled by the global economy overseas, which contributed disproportionately to our decline in sales," said RBC Life Sciences President and CEO John W. Price. "We did, however, see sales in this channel begin to increase late in the year as global economic conditions also began to show signs of improvement.  A bright spot in 2009 was the growth of our North American network marketing base. Sales domestically grew more than 4% percent in 2009 compared to the previous year."

Mr. Price also said that RBC Life Sciences is now compliant with industry-wide, FDA-required Good Manufacturing Practices (GMP). "The company invested substantial resources to achieve GMP compliance during 2009 and will continue to do so annually to maintain our GMP status," said Mr. Price. GMPs ensure that companies adhere to practices that promote product safety, quality and efficacy.

About RBC Life Sciences
Through U.S. and Canadian subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. MPM Medical, the company's medical products subsidiary, develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

                              RBC Life Sciences, Inc.
                           Summary Results of Operations
                       (in thousands, except per share data)
                                                  Years Ended December 31,
                                                 2009                  2008
                                                 ----                  ----
    Net sales                                 $24,925               $30,409
    Gross profit                               12,802                15,494
    Operating profit (loss)                      (160)                2,852
    Earnings (loss) before income taxes          (324)                2,677
    Provision for income taxes                     11                 1,061
    Net earnings (loss)                          (335)                1,616
    Earnings (loss) per share – basic          $(0.02)                $0.08
    Earnings (loss) per share – diluted         (0.02)                 0.07
    Weighted average shares
     outstanding – basic                       21,921                21,465
    Weighted average shares
     outstanding – diluted                     21,921                22,839
                             RBC Life Sciences, Inc.
                            Condensed Balance Sheets
                                 (in thousands)
                                         December 31,          December 31,
                                         ------------          ------------
                                                 2009                  2008
                                                 ----                  ----
    Cash and cash equivalents                  $3,972                $4,973
    Inventories                                 5,344                 5,707
    Other current assets                        1,914                 2,245
                                                -----                 -----
      Total current assets                     11,230                12,925
    Other assets                                7,383                 6,841
                                                -----                 -----
      Total assets                            $18,613               $19,766
                                              =======               =======
    Liabilities and shareholders' equity
    Accounts payable and accrued
     liabilities                               $2,729                $3,228
    Deferred revenue                            3,669                 4,279
    Other current liabilities                     156                   144
                                                  ---                   ---
      Total current liabilities                 6,554                 7,651
    Other liabilities                           2,840                 2,728
    Shareholders' equity                        9,219                 9,387
                                                -----                 -----
      Total liabilities and
       shareholders' equity                   $18,613               $19,766
                                              =======               =======

SOURCE RBC Life Sciences, Inc.

Back to top



SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Responds to the National Acadamy of Sciences Report that Millions of Americans Get Sick Yearly from Contaminated Water
2. Moravia Worldwide to Present Webinar on Life Sciences Translation 101
3. SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program
4. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
5. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
6. Vista LifeSciences Partners with Vangard Voice Systems to Voice-Enable Medical Data Collection
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
8. Gems Medical Sciences Created to Focus on Medical & Life Science Fluid Handling
9. AMD Global Telemedicine Inc. and Texas Tech University Health Sciences Center Bring High-Tech Health Care to Children of Texas
10. Bariatric Advantage, a Division of Catalina Lifesciences, Inc. Announces Appointment of Bret Petkus to Vice-President of North American Sales.
11. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
Post Your Comments:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology: